Westwood Bioscience, Inc. is developing Silicasome nanoparticle technology for enhanced delivery and reduced toxicity of chemotherapeutics drugs.
Market:Liposomes as a drug delivery system have serious drawbacks including: autoimmune responses, accumulation in tissues, inconsistent drug release, short half-life and often similar toxicity of the payload to unencapsulated drug. Silicasomes are a next generation nanoparticle technology that overcome these drawbacks and are biodegradable with no observed toxicities. The market for drug delivery systems is expected to reach $137B in the U.S. and $225.8B worldwide by 2020.
Technology:Silicasomes are comprised of a hollow mesoporous silica core surrounded by a lipid bilayer to enhance the delivery of a therapeutic. Mesoporous silica exhibits exceptionally ordered pores which can be loaded with a controlled amount of a desired drug payload. Optionally, a second drug can be loaded into the lipid bilayer coating allowing ratiometric delivery of multiple drugs. Targeting motifs can be added to further facilitate tumor delivery and reduce off-target effects.